LONDON (Alliance News) - Biopharmaceutical research firm Proteome Sciences PLC said Friday Non-Executive Director Martin Diggle purchased 469,866 shares at a price of 3.60 pence each on Thursday.
Diggle acquired stock through investment firm Vulpes Life Sciences Fund, where he is also a director. The transaction had a total value of GBP1.7 million.
Diggle's holding following the deal totalled 58.7 million shares, accounting for 20%.
Proteome Sciences shares were untraded on Friday, last quoted at 3.61p each.
Proteome (PRM)